Page 89 - Read Online

patients (n = 77) with many poorer prognostic factors than 9. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K,
ours. Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J,
Wilson KS, Gascoyne RD, Connors JM. Introduction
DLBCNHL is potentially curable after treated of combined CHOP plus rituximab therapy dramatically
with anthracycline-containing regimens; however, improved outcome of diffuse large B-cell lymphoma in British
a signifi cant proportion of patients do not receive Columbia. J Clin Oncol 2005;23:5027-33.
anthracyclines, particularly doxorubicin for various 10. Armitage JO. The place of third-generation regimens in the
reasons, e.g. older age, expected poor tolerance or treatment of adult aggressive non-Hodgkin’s lymphoma. Ann
Oncol 1991;2 Suppl 1:37-41.
signifi cant comorbidities. These patients present an 11. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP,
[12]
unmet medical need. Measures that may decrease Grozea PN, Wilson HE. Effect of age on therapeutic outcome
toxicity and improve anthracycline tolerance includes in advanced diffuse histiocytic lymphoma: the Southwest
adequate supports (e.g. hematopoietic growth factors), Oncology Group experience. J Clin Oncol 1986;4:295-305.
dose reductions, increase in infusion time, the addition 12. Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E.
of cardio-protectants (e.g. dexrazoxane). [16,18,26,34,35] An Treatment of diffuse large B-cell lymphoma in the elderly:
alternative less-toxic and more tolerable anthracycline may regimens without anthracyclines are common and not futile.
Leuk Lymphoma 2015;56:65-71.
be considered if feasible, e.g. liposomal doxorubicin, [36,37] 13. Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D,
[39]
[40]
epirubicin, mitoxantrone or pixantrone. In case Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E,
[38]
an anthracycline cannot be used, substitution with other Salles B, Dumontet C, Brière J, Coiffi er B. Elderly
agents, e.g. etoposide or gemcitabine may better than patients with aggressive non-Hodgkin’s lymphoma: disease
omission. Addition of the immunotherapy agent like presentation, response to treatment, and survival - a Groupe
[41]
rituximab to non-anthracycline-containing regimens d’Etude des Lymphomes de l’Adulte study on 453 patients
older than 69 years. J Clin Oncol 1997;15:2945-53.
signifi cantly improves the outcomes and should be 14. Cheson BD, Horning SJ, Coiffi er B, Shipp MA, Fisher RI,
considered. Non-anthracycline-containing regimens Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A,
[18]
with the addition of rituximab produced equivalent Cabanillas F, Klippensten D, Hiddemann W, Castellino R,
outcomes to anthracycline-containing regimens. [12,18,19] Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP.
Report of an International Workshop to Standardize Response
References Criteria for Non-Hodgkin’s Lymphomas. NCI Sponsored
International Working Group. J Clin Oncol 1999;17:1244.
1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of 15. Gottlieb JA, Gutterman JU, McCredie KB, Rodriguez V,
cancer prevalence for 27 sites in the adult population in 2008. Frei E 3rd. Chemotherapy of malignant lymphoma with
Int J Cancer 2013;132:1133-45. adriamycin. Cancer Res 1973;33:3024-8.
2. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, 16. Luminari S, Montanini A, Federico M. Anthracyclines: a
Kamel H. Cancer incidence in egypt: results of the national cornerstone in the management of non-Hodgkin’s lymphoma.
population-based cancer registry program. J Cancer Epidemiol Hematol Rep 2011;3:e4.
2014;2014:437971. 17. Armitage JO, Fyfe MA, Lewis J. Long-term remission
3. Boffetta P. Epidemiology of adult non-Hodgkin lymphoma. durability and functional status of patients treated for diffuse
Ann Oncol 2011;22 Suppl 4:iv27-31. histiocytic lymphoma with the CHOP regimen. J Clin Oncol
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, 1984;2:898-902.
Stein H, Thiele J, Vardiman JW. WHO Classifi cation of 18. Link BK, Brooks J, Wright K, Pan X, Voelker M,
Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Chrischilles E. Diffuse large B-cell lymphoma in the
Geneva: World Health Organization; 2008. elderly: diffusion of treatment with rituximab and survival
5. Herzog CM, Dey S, Hablas A, Khaled HM, Seifeldin IA, advances with and without anthracyclines. Leuk Lymphoma
Ramadan M, El-Hamzawy H, Wilson ML, Soliman AS. 2011;52:994-1002.
Geographic distribution of hematopoietic cancers in the Nile 19. Grann VR, Hershman D, Jacobson JS, Tsai WY, Wang J,
delta of Egypt. Ann Oncol 2012;23:2748-55. McBride R, Mitra N, Grossbard ML, Neugut AI. Outcomes
6. Abdelhamid T, Samra M, Ramadan H, Mehessin M, and diffusion of doxorubicin-based chemotherapy among
Mokhtar N. Clinical prognostic factors of diffuse large B cell elderly patients with aggressive non-Hodgkin lymphoma.
non-Hodgkin lymphoma: a retrospective study. J Egypt Natl Cancer 2006;107:1530-41.
Canc Inst 2011;23:17-24. 20. Keating NL, Landrum MB, Lamont EB, Bozeman SR,
7. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK,
Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of Rabin M, McNeil BJ. Quality of care for older patients with
a standard regimen (CHOP) with three intensive chemotherapy cancer in the Veterans Health Administration versus the private
regimens for advanced non-Hodgkin’s lymphoma. N Engl J sector: a cohort study. Ann Intern Med 2011;154:727-36.
Med 1993;328:1002-6. 21. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD,
8. Coiffi er B, Thieblemont C, Van Den Neste E, Lepeu G, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M,
Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Carter WB. Patterns of chemotherapy administration in
Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. patients with intermediate-grade non-Hodgkin’s lymphoma.
Long-term outcome of patients in the LNH-98.5 trial, the Oncology (Williston Park) 2001;15:1296-306.
fi rst randomized study comparing rituximab-CHOP to 22. Jurczak W, Szmit S, Sobocinski M, Machaczka M,
standard CHOP chemotherapy in DLBCL patients: a study Drozd-Sokolowska J, Joks M, Dzietczenia J, Wróbel
by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood T, Kumiega B, Zaucha JM, Knopińska-Posłuszny
2010;116:2040-5. W, Spychałowicz W, Prochwicz A, Drohomirecka A,

82 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦